The 340(b) Drug Pricing Program is facing unprecedented pressure. A growing number of pharmaceutical manufacturers are imposing restrictions on contract pharmacy access, making it harder—and more expensive—for covered entities to get the discounted medications they rely on to serve vulnerable populations.
These changes are not just bureaucratic headaches. They are direct threats to the stability of safety-net providers and the communities they serve.
What’s Happening?
Pharmaceutical companies argue that restrictions are necessary to reduce duplicate discounts and better track distribution. But for health centers and hospitals, these moves drastically reduce the reach and financial viability of the 340(b) program, particularly for rural and underserved communities that depend on contract pharmacies for medication access.
In response, many health systems and advocacy groups have turned to legal action. However, lawsuits take time—and patients can’t wait.
What’s at Stake?
When contract pharmacy access is cut off or limited:
-
Covered entities lose critical savings
-
Patients may have fewer pharmacy options
-
Continuity of care becomes harder to manage
-
Operations become more costly and complex
The result? A growing number of providers are being forced to make impossible choices—scale back services, lay off staff, or turn away patients.
The American Exchange Advantage
In times like these, your choice of 340(b) partner is everything. At American Exchange, we bring more than just services—we bring stability, strategy, and resilience.
Here’s how we help our clients thrive even under market pressure:
-
Compliance-First Approach: Ensuring every action meets regulatory standards, even as rules shift.
-
Customized Pharmacy Strategy: Helping you adapt to limited contract pharmacy access without losing impact.
-
Financial Optimization: Identifying opportunities to maximize savings and reinvest in care.
-
Operational Flexibility: Supporting transitions, dual partnerships, and innovations like specialty pharmacy integration.
We know the terrain—and we know how to build a sustainable path forward.
Why It Matters Now
As manufacturer restrictions grow and pricing pressure intensifies, reactive strategies won’t cut it. Covered entities must act decisively to protect their missions, patients, and bottom line.
Whether you’re already feeling the squeeze or just want to prepare for what’s next, now is the time to strengthen your 340(b) model.
Let’s Talk About What’s Possible
Don’t wait for the pressure to break your program. Let’s work together to design a resilient 340(b) strategy that keeps care accessible and your operations strong—no matter what the manufacturers do next.
Reach out to American Exchange today. Because your patients—and your mission—deserve a partner who’s ready for anything.
